DWP223 / Daewoong Pharma - LARVOL DELTA

Transforming treatment paradigms: A cutting-edge polθ Inhibitor (DWP223) targeting PARP resistance in BRCA-mutant cancers (AACR 2025) - "The compound's favorable pharmacokinetic profile and robust safety data across multiple species underscore its suitability for clinical development, highlighting the opportunity to reduce hematological toxicity and target PARP inhibitor-resistant cancers.Collectively, DWP223 represents a promising therapeutic candidate, either as a standalone treatment or in combination with PARPi, for targeting HR-deficient cancers and potentially overcoming PARPi resistance. DWP223 is advancing toward IND filing in 2025."

Oncology • BRCA • BRCA1 • BRCA2 • HRD

Daewoong Pharmaceutical to unveil 3 anticancer pipelines at AACR 2025 (Korea Biomedical Review) - "Daewoong Pharmaceutical, a Korean drugmaker, said on Friday that it will unveil three anticancer pipelines at the 2025 American Association for Cancer Research (AACR) annual meeting, taking place from April 25 to 30 in Chicago, the U.S. The three investigational drugs are targeted therapy DWP216, immunotherapy DWP217, and synthetic lethality drug DWP223....Daewoong will showcase preclinical results of these three candidate drugs in four posters....DWP216 reduced cancer cell resistance and enhanced the effectiveness of existing anticancer drugs in non-small cell lung cancer and pancreatic cancer with EGFR and KRAS mutations. DWP217, the immunotherapy, proved more effective than current arginase inhibitors in animal studies, improving the immunosuppressive tumor environment and enabling immune cells to attack cancer more aggressively. DWP223, the synthetic lethality drug, showed potent anti-cancer effects at low doses in animal studies."

Preclinical • Non Small Cell Lung Cancer